---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089298"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:26:33.260668+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cyclacel Q2 2023 net loss $5.4M; cash $10.2M, runway to end of 2023

## Summary
- Net loss of $5.4M for Q2 2023 vs $4.6M Q2 2022; cash $10.2M at June 30, 2023 (down from $18.3M Dec 2022).
- R&D expenses $4.7M in Q2 2023 vs $4.2M Q2 2022; fadraciclib $3.0M, plogosertib $1.4M.
- Cash expected to fund programs through end of 2023; discretionary cuts could extend to Q2 2024.
- Phase 1/2 data for fadraciclib and plogosertib expected in 2023; tumor shrinkage observed in several cancer types.

## SEC filing metadata
- accession: 0001104659-23-089298
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/0001104659-23-089298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/tm2323211d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089298
- JSON: https://secwatch.observer/filing/0001104659-23-089298.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089298.txt

## Key facts
- Earnings Releases
  Bio Green Med Solution, Inc. reported second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023, was $5.4 million.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss for the three months ended June 30, 2023, was $5.4 million
  - Result: reported results
  source text: Net loss for the three months ended June 30, 2023, was $5.4 million, compared to $4.6 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/0001104659-23-089298-index.htm
- Earnings Releases
  Bio Green Med Solution, Inc. reported financial results for six months ended June 30, 2023.
  - Period: six months ended June 30, 2023
  - Result: reported results
  source text: Net loss for the three months ended June 30, 2023, was $5.4 million, compared to $4.6 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923089298/0001104659-23-089298-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.